Arch Venture Corp »

Beam Therapeutics shares owned by Arch Venture Corp

Quarter-by-quarter ownership of Beam Therapeutics (BEAM) shares owned by Arch Venture Corp from 13F filings

Historical chart of Arch Venture Corp investment in Beam Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Beam Therapeutics held by Arch Venture Corp consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Beam Therapeutics by Arch Venture Corp

Quarter filed Position value Share count Share price at filing
2024-06-30 $128M 5.4M 23.43

More positions owned by Arch Venture Corp

Beam Therapeutics (BEAM)
Rapport Therapeutics
Erasca (ERAS)
Verve Therapeutics (VERV)
Gossamer Bio (GOSS)
Q32 Bio (QTTB)
Unity Biotechnology Com New (UBX)
Singular Genomics Systems Com New
Cero Therapeutics Holdings Class A Com (CERO)

View all positions for Arch Venture Corp

Top funds holding Beam Therapeutics

Farallon Capital Management
Vanguard Group
BlackRock
ARK Investment Management
Arch Venture Corp
FMR
State Street Corporation
MWG Management
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
Temasek Holdings
Geode Capital Management
Redmile Group
Bellevue Group
T. Rowe Price Associates

View all funds holding Beam Therapeutics